Compare STDN & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STDN | HTFL |
|---|---|---|
| Founded | 2024 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2026 | 2025 |
| Metric | STDN | HTFL |
|---|---|---|
| Price | $11.56 | $54.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $17.25 | ★ $50.50 |
| AVG Volume (30 Days) | 265.4K | ★ 1.6M |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $176,034,000.00 |
| Revenue This Year | $439.23 | $41.24 |
| Revenue Next Year | $259.21 | $24.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.92 |
| 52 Week Low | $7.05 | $20.13 |
| 52 Week High | $17.34 | $60.56 |
| Indicator | STDN | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 54.39 |
| Support Level | $11.42 | $46.46 |
| Resistance Level | $13.73 | N/A |
| Average True Range (ATR) | 0.81 | 3.18 |
| MACD | -0.07 | 0.24 |
| Stochastic Oscillator | 10.06 | 58.09 |
Standard Nuclear Inc is an independent advanced nuclear fuel company. The company designs, engineers, and manufactures advanced nuclear fuels, with a primary focus on TRISO fuel for advanced reactors. Its operations include industrial-scale TRISO fuel manufacturing and the development of fuel for advanced reactors that utilize TRISO fuel. The company operates in a single operating and reportable segment, as it is engaged in a single business activity of TRISO production. It derives revenue from fuel development and services agreements. Geographically, the maximum revenue is generated from the United States.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.